Prognostic Utility of Right Ventricular Remodeling Over Conventional Risk Stratification in Patients With COVID-19

Jiwon Kim1, Alexander Volodarskiy2, Razia Sultana3

  • 1Division of Cardiology, Weill Cornell Medicine, New York, New York; Department of Radiology, Weill Cornell Medicine, New York, New York.

Insights

Right ventricular remodeling, including dysfunction and dilation, independently predicts mortality in COVID-19 patients. This finding offers crucial prognostic insights beyond existing clinical and biomarker assessments for coronavirus disease 2019.

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Pulmonology

Background:

  • Coronavirus disease 2019 (COVID-19) is associated with an increased risk of right ventricular (RV) dysfunction and dilation.
  • The prognostic significance of adverse RV remodeling in COVID-19 patients remains unclear.

Purpose of the Study:

  • To determine if adverse RV remodeling (dysfunction/dilation) predicts COVID-19 prognosis independently of established clinical and biomarker risk factors.
  • To assess the independent prognostic utility of RV remodeling in hospitalized COVID-19 patients.

Main Methods:

  • A study of 510 consecutive COVID-19 inpatients across three New York City hospitals.
  • Transthoracic echocardiography images were centrally analyzed by a core laboratory blinded to clinical and biomarker data.
  • Assessment of RV dilation and dysfunction, and correlation with inpatient mortality and hospital discharge.

Main Results:

  • 35% of patients exhibited RV dilation and 15% showed RV dysfunction.
  • RV dysfunction and dilation independently predicted mortality (HR: 2.57 and 1.43, respectively).
  • Adverse RV remodeling provided additional risk stratification beyond biomarkers, with the highest mortality risk in patients with both RV remodeling and positive biomarkers.

Conclusions:

  • Adverse right ventricular remodeling is an independent predictor of mortality in COVID-19 patients.
  • Echocardiographic assessment of RV remodeling offers prognostic value beyond standard clinical and biomarker evaluations.
  • These findings highlight the importance of evaluating RV status in COVID-19 management.
Abstract

Related Concept Videos

Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
209
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
227
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
288
Aortic Regurgitation II: Clinical Features and Diagnostic Tests01:22

Aortic Regurgitation II: Clinical Features and Diagnostic Tests

Aortic valve regurgitation (AR) occurs when the aortic valve fails to close properly, allowing blood to flow backward from the aorta into the left ventricle. This backflow can result in two distinct clinical presentations: acute and chronic AR, each characterized by its own set of symptoms and physical findings.Acute Aortic RegurgitationAcute AR presents with a sudden onset of severe symptoms. Patients typically experience profound dyspnea (shortness of breath), chest pain, and signs of left...
239
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
172
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
208